Prior studies have shown that among patients with chronic kidney disease not yet on dialysis, the faster progression of kidney injury in men than in women is, at least partly, explained by sex differences in ambulatory blood pressure (BP) control. The present study aimed to investigate potential differences in the levels of ambulatory BP and intensity of antihypertensive treatment between men and women with end-stage kidney disease undergoing long-term peritoneal dialysis (PD). In a case-control design, 48 male PD patients were matched for age and heart failure status with 48 female patients in a 1:1 ratio. Ambulatory BP monitoring was performed with an oscillometric device, the Mobil-O-Graph (IEM, Stolberg, Germany). The BP-lowering medications actually taken by the patients were prospectively recorded. No gender-related differences were observed in 24 h systolic BP (129.0 ± 17.9 vs. 128.5 ± 17.6 mmHg, p = 0.890). In contrast, 24 h diastolic BP was higher in men than in women (81.5 ± 12.1 vs. 76.8 ± 10.3 mmHg, p = 0.042). As compared with women, men were being treated with a higher average number of antihypertensive medications daily (2.4 ± 1.1 vs. 1.9 ± 1.1, p = 0.019) and were more commonly receiving calcium-channel-blockers (70.8% vs. 43.8%, p = 0.007) and β-blockers (85.4% vs. 66.7%, p = 0.031). In conclusion, the present study shows that among PD patients, the levels of ambulatory BP and intensity of antihypertensive treatment are higher in men than in women. Longitudinal studies are needed to explore whether these gender-related differences in the severity of hypertension are associated with worse cardiovascular outcomes for male patients undergoing PD.
Background: For patients on hemodialysis, routine blood pressure (BP) measurements taken shortly before or after dialysis provide inaccurate estimates of the BP load during the interdialytic period. In this study, we used peridialytic recordings in combination with interdialytic ambulatory BP monitoring (ABPM) aiming to provide a more precise assessment of hypertension in a sample of 70 stable hemodialysis patients. Methods: The evaluation of hypertension in the study cohort was performed using the following approaches: (i) routine predialysis and postdialysis BP measurements taken by the dialysis-unit staff were prospectively recorded over six consecutive dialysis sessions; (ii) ABPM was performed using the Microlife WatchBPO3 device (20 min intervals during an entire 44 h interdialytic period). The diagnostic thresholds of hypertension were ≥140/90 mmHg for predialysis, ≥130/80 mmHg for postdialysis and ≥130/80 mmHg for 44 h ambulatory BP, respectively. Patients receiving ≥1 antihypertensive medication also were classified as hypertensives. Results: The prevalence of hypertension was 88.6% by predialysis, 92.9% by postdialysis and 90.0% by ambulatory BP measurements. In all, 87.1% of patients were being treated for hypertension. When the combination of predialysis and 44 h ambulatory BP was evaluated, the prevalence of sustained normotension, white-coat, masked and sustained hypertension was 52.9%, 21.4%, 5.7% and 20.0%, respectively. A similar distribution of patients into these phenotypes was observed when postdialysis BP was used for the classification of the severity of hypertension (50.0%, 24.3%, 5.7% and 20.0% for sustained normotension, white-coat, masked and sustained hypertension, respectively). Interdialytic ABPM revealed that just one patient had abnormal BP solely during the daytime period. Conversely, isolated nocturnal hypertension was diagnosed in 27.1% of patients. Conclusions: This study shows that among patients on hemodialysis, peridialytic BP is an inaccurate proxy of interdialytic ambulatory BP. In approximately 30% of patients, there is discordance between routine peridialytic recordings and interdialytic ABPM for the diagnosis of hypertension. ABPM also facilitates the diagnosis of isolated nocturnal hypertension, which is another frequent BP phenotype in this high-risk patient population.
Oxidative stress (OS) is highly prevalent in chronic kidney disease (CKD), yet its clinical significance and association with cardiovascular disease (CVD) has not been yet clearly demonstrated. In this cohort study, 477 adults with CKD at various stages and 20 healthy controls were enrolled. In all participants, an extensive panel of OS biomarkers was measured. Malondialdehyde (MDA) was correlated with glomerular filtration rate (eGFR) and carotid intima media thickness (cIMT) (p = 0.008 and p = 0.024, respectively, according to Spearman’s rho). Advanced oxidation protein products (AOPPs) were correlated with the urine protein-to-creatinine ratio (uPCR), parathormone (PTH) and eGFR (p = 0.048, p = 0.025 and p = 0.045 respectively, according to Spearman’s rho) and oxidized albumin (oxALB) was correlated with PTH (p = 0.032) and pulse wave velocity (PWV) (p = 0.017). The antioxidant enzyme superoxide dismutase (SOD) was correlated with PWV (p = 0.042), urea (p < 0.001), uPCR (p = 0.024), and eGFR (p < 0.001). Meanwhile, catalase (CAT) was correlated with eGFR (p = 0.029) and indices of central pressure. Xanthine oxidase (XO) was correlated with the duration of CVD and PWV. Multivariate analysis showed that kidney function and/or arterial stiffness and CVD were independent predictors of all OS markers.